Voting Rights and Capital

Click here - to use the wp menu builder

News Room

Less than 1 min.Read

By Investing Today

July 31, 2025

Total Voting Rights

In conformity with the Disclosure Guidance and Transparency Rules, we hereby notify the market of the following:

Shell plc’s capital as at July 31, 2025, consists of 5,876,351,658 ordinary shares of €0.07 each. Shell plc holds no shares in Treasury.

The figure, 5,876,351,658, may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Shell plc under the FCA’s Disclosure Guidance and Transparency Rules.

Note: This announcement is made pursuant to Disclosure Guidance and Transparency Rule 5.6.1 and as such, the above figure includes shares purchased by Shell plc as part of its share buy-back programme but not yet cancelled.

Enquiries

Shell Media Relations
International +44 (0)207 934 5550; U.S. and Canada: Contact form

LEI number of Shell plc: 21380068P1DRHMJ8KU70
Classification: Total number of voting rights and capital

Hot this week

Topics

Popular Categories

News RoomFeatured CompaniesVideos

RCI Banque: ‘’2025 First Half Business Report is now available’’

Vornado Declares Quarterly Dividends On Preferred Shares

NEW MID-TERM FINANCIAL TARGETS – ISS TO ACCELERATE HIGHER-QUALITY GROWTH AND EXPAND MARGINS

Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer

Capgemini signs a definitive agreement to sell Capgemini Government Solutions

Michelin | Disclosure of the total number of voting rights and of the number of shares making up the company’s capital

Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Topics

NEW MID-TERM FINANCIAL TARGETS – ISS TO ACCELERATE HIGHER-QUALITY GROWTH AND EXPAND MARGINS

Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer

Capgemini signs a definitive agreement to sell Capgemini Government Solutions

Michelin | Disclosure of the total number of voting rights and of the number of shares making up the company’s capital

Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement

Exodus Movement, Inc. August 2026 — Monthly Metrics

Apollo to Present at the Bank of America 31st Annual Financials CEO Conference

Related Articles

NEW MID-TERM FINANCIAL TARGETS – ISS TO ACCELERATE HIGHER-QUALITY GROWTH AND EXPAND MARGINS

Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer

Capgemini signs a definitive agreement to sell Capgemini Government Solutions

Michelin | Disclosure of the total number of voting rights and of the number of shares making up the company’s capital

Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Company

Headlines

NEW MID-TERM FINANCIAL TARGETS – ISS TO ACCELERATE HIGHER-QUALITY GROWTH AND EXPAND MARGINS

Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer

Capgemini signs a definitive agreement to sell Capgemini Government Solutions

Michelin | Disclosure of the total number of voting rights and of the number of shares making up the company’s capital

Newsletter